Data from EMC - Curated by EPG Health - Last updated 30 September 2016


Targocid is indicated in adults and in children from birth for the parenteral treatment of the following infections:

- complicated skin and soft tissue infections,

- bone and joint infections,

- hospital acquired pneumonia,

- community acquired pneumonia,

- complicated urinary tract infections,

- infective endocarditis,

- peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD),

- bacteraemia that occurs in association with any of the indications listed above.

Targocid is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.

Where appropriate, teicoplanin should be administered in combination with other antibacterial agents.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.


Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Load more

Related Content

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder Sanofi-aventis